20n Bio: Malvern artificial intelligence-powered drug discovery firm raises $3.3M

An artificial intelligence-powered drug discovery company has raised $3.3 million to advance it work designing new therapeutic proteins. Malvern-based 20n Bio's seed funding round was led by BlueRun Ventures in China. The company plans to use the proceeds from the equity financing to expand its scientific team and its discovery platform, and to start multiple early studies in oncology and other genetic diseases. Mingfu Zhu founded 20n Bio in September. The company's mission is to use computer...